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charge for pharmaceuticals of MRSA bacteremia patients was
$2411 and that of MSSA bacteremia patients was $1289. The
median length of hospitalization after the development of MRSA
patients who survived was 32.5 days and that of MSSA bac-
teremia control patients who survived was 18 days. CONCLU-
SION: Antibiotic resistance in Staphylococcus aureus bacteremia
increased direct medical cost by 26%. The results of this study
indicate that the MRSA infection is associated with increased
medical cost and prolonged hospital stay.
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OBJECTIVES: Zidovudine (ZDV) use has been shown to be
associated with anemia. Our objective was to assess the impact
of anemia on medical resource use and cost in patients treated
with a ZDV-containing HAART regimens. METHODS: Case-
control study using HIV Insight, which contains medical chart
data from 21 US HIV care centers. ZDV-naïve patients who
began a ZDV-containing HAART regimen on any date from
January 2000 to June 2004 were assessed for baseline anemia
(Hb < 11 g/dL). Those without anemia (N = 529) were followed
through June, 2005 or until they had anemia or changed to a
non-ZDV-containing regimen. Those with anemia (N = 69) were
followed until anemia worsened (drop ≥ 1.0 g/dL). Patients with
an incident anemia event (initiating or worsening) with ≥12
months of follow-up were selected as cases. Controls were
matched on baseline anemia, CD4 < 350, gender and time
period. Medical resource use was tabulated during the 1-year
post anemia period. Costs were estimated for health care encoun-
ters using external data for prices expressed in 2006 $US.
RESULTS: Cases included 70 patients with anemia (57 initiat-
ing, 13 worsening.) Cases had greater use of medical resources
than controls: 9.2 vs 5.0 (P < 0.001) ofﬁce visits per year, 33%
vs 3% hospitalized (P < 0.001), 21% vs 3% treated with EPO
(P = 0.001) and 7% vs 0% (P = 0.058) with a transfusion. Cases
had higher average annual costs than controls; $37,124 vs
$25,141 (P = 0.002). Cost components included EPO $1,369 vs
$181 (P = 0.002), antiretrovirals $18,299 vs $19,837 (P =
0.461), other drugs $12,488 vs $3,763 (P = 0.005) and hospital
stays, $3,114 vs $169 (P < 0.001). CONCLUSION: Patients
treated with ZDV who experienced anemia required signiﬁcantly
more medical care and reported higher medical cost than patients
without anemia.
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OBJECTIVES: Determine the economic impact and resource uti-
lization of adult HIV and HCV co-infected hemophilia patients
in a managed care population in the United States. METHODS:
Retrospective claims database analysis from 1/97 to 4/04.
Patients continuously enrolled for at least 6 months and >18
years of age were included. Hemophilia patients were identiﬁed
using ICD-9CM, HCPCS, and NDC codes. Four cohorts for
analysis were established: Hemophilia only Hemophilia + HIV,
Hemophilia + HCV, Hemophilia + HIV + HCV. The main out-
comes of study were costs associated with all pharmacy and
medical claims, inpatient hospitalizations (frequency and length
of stay) and ofﬁce visit distribution by physician specialty.
RESULTS: Annual cost of care was $85,616 for the hemophilia
only cohort, $99,180 for the HIV cohort, $105,676 for the HCV
cohort and $129,889 for HIV/HCV co-infected cohort in 2004
dollars. Clotting factor accounted for approximately 70–81% of
total costs. The Hemophilia only, HCV, HIV, HIV/HCV infected
hemophilia cohorts had prescription drug costs of $2,341,
$8,867, $6,256 and $12,060, respectively. Approximately 17%
of hemophilia only, 19% of HCV, and 27% of the HIV/HCV
cohorts were hospitalized during the study period (p = 0.45).
Hospitalizations that were hemophilia related accounted for
43% of total hospitalizations for the hemophilia only cohort and
16% for the HIV/HCV cohort (p = 0.30). No signiﬁcant differ-
ence in inpatient length of stay was found. There was a differ-
ence in the mean number of ofﬁce visits among the cohorts (p =
0.022) with the HIV/HCV cohort having more visits than the
hemophilia only group, 18.3 vs. 7.3, respectively (p = 0.05).
CONCLUSION: Although we were not able to control for sever-
ity, the presence of HIV and HCV co-infection in hemophiliacs
is associated with an increase in annual costs by up to 52%.
Increased clotting factor use and prescription drug costs in the
virally infected groups account for most of the increase in costs.
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OBJECTIVES: To estimate the long-term health and economic
impact of managing CHB with entecavir instead of adefovir
treatment in the US, based upon projected clinical beneﬁts from
HBV DNA reduction observed in trials. METHODS: We took
the perspective of a comprehensive payer responsible for all
direct health care expenditures. A decision simulation model was
developed to consider a hypothetical cohort of 1000 lamivudine
refractory CHB patients. Multivariate-adjusted relative risks for
ﬁve HBV DNA categories were derived from the published
R.E.V.E.A.L.-HBV study. These results were applied to the
patients with simulation of their HBV DNA data derived from
summary statistics reported in separate entecavir and adefovir
clinical trials. Entecavir and Adefovir daily costs were assumed
$20.52 and $19.11 based on the wholesale acquisition prices.
Life expectancy estimates, direct medical cost of and utility
scores for different phases of CHB were estimated from pub-
lished US speciﬁc data. Viral resistance due to treatment was
included. RESULTS: Entecavir was superior to adefovir for the
mean reduction in serum HBV DNA by PCR assay (log10
copies/mL) adjusted for lamivudine effect, with reductions of
4.97 versus 4.00, respectively. More patients reached unde-
tectable viral load level with entecavir than adefovir treatment
at Week 48 (19.5% vs 9.6%). In the reference case, for 1000
patients aged 40 years, compared with adefovir, ten years of ente-
cavir treatment avoided 25 compensated cirrhosis, 3 decompen-
sated cirrhosis, and 15 HCC, resulting in 0.235 quality-adjusted
life year (QALY) gain at an incremental cost of $2563 per patient
(3% discounted). The incremental cost of using entecavir was
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$10,899 per QALY gained (in 2006). These results were robust
to sensitivity analyses. CONCLUSION: Entecavir was projected
to be clinically and economically attractive in treating lamivu-
dine refractory CHB patients. Further economic modeling upon
the availability of head-to-head clinical trials will be helpful to
conﬁrm these ﬁndings.
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OBJECTIVES: The aim of this study was to collect comparable
and reliable data on the antibiotic therapy in Slovakia during the
period 1996–2005. The special interest was paid to the trend of
antibiotic usages. METHODS: Data of wholesalers (following
ATC/DDD), who are legally obliged provide this information to
the Slovak Institute for Drug Control, was used for the analysis.
The results were expressed in ﬁnance units (€) and deﬁned daily
doses per 1000 inhabitants per day (DID). RESULTS: The col-
lected data showed slight decrease in antibiotic consumption
from 1996 to 2005 in term of DID—in 1996 (26.42), in 2000
(25.05) and in 2005 (25.11). We can see a noticeable increase 
in consumption of macrolides (DID)—in 1996 (3.08), in 2000
(2.99) and in 2005 (4.44) and signiﬁcant increase in ﬂuoro-
quinolones consumption—in 1996 (0.73), in 2000 (1.55) and 
in 2005 (2.01). A signiﬁcant decrease in ﬁrst-generation
cephalosporins consumption—in 1996 (1.17), in 2000 (1.13)
and in 2005 (0.45), and a noticeable increase in consumption of
second-generation cephalosporins—in 1996 (0.79), in 2000
(1.24) and in 2005 (2.27) can be seen from this analysis. The
results show that consumption of combinations of penicillins
incl. beta-lactamase has increased—in 1996 (2.24), in 2000
(3.72) and in 2005 (4.83), but consumption of beta-lactamase
sensitive penicillins has decreased—in 1996 (4.79), in 2000
(4.11) and in 2005 (2.81) in term of DID. From this study, the
stable antibiotics consumption in ﬁnancial term—in 1996
(39,171,000 €), in 2000 (42,556,000 €) and in 2005 (39,985,000
€) can be seen. CONCLUSION: Inseparable components of the
Slovak drug policy must be viewed realistically with regard to
the antibiotic consumption. Adherence to principles of antibiotic
policy lead to fundamental short and long term ﬁnancial savings
within health care systems.
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OBJECTIVES: HIV/AIDS incidence and mortality rates have
decreased in the U.S. since 1996 due to the use of effective anti-
retroviral medications and prevention campaigns. The objective
of this study is to analyze the trends of prices, utilization, and
market shares of antiretroviral medications in the U.S. Medicaid
program. METHODS: Antiretroviral drugs include protease
inhibitors (PIs), nucleoside analogs (NRTIs), non-nucleoside
reverse transcriptase inhibitors (NNRTIs), and fusion inhibitors
(FIs). Reimbursement and utilization data from 1991 to 2005
are provided by the Centers for Medicare & Medicaid Services.
Descriptive time-series analysis was used to assess quarterly pre-
scription numbers, amount of reimbursement, and spending per
prescription. RESULTS: The total reimbursement for antiretro-
viral drugs in the U.S. Medicaid program increased from $ 30.58
million in 1991 to $1.37 billion in 2005. In 2005, NRTIs as a
class had the highest reimbursement market share. These drugs
alone accounted for $608.6 million in Medicaid reimbursements
(44.4% of spending on antiretrovirals). The PIs came in second
at $560.4 million (40.9 percent), and the NNRTIs were third 
at $161.4 million (11.8%). The total number of prescriptions
increased dramatically from 168,914 in 1991 to 1.99 million in
1998, and 2.73 million in 2005. The number of prescriptions 
for NRTIs reached 1.38 million in 2005. Prescriptions for PIs
increased from 114 in 1995 to 928,949 in 2005. The diffusion
of prescriptions for NNRTIs was also rapid from 1,339 pre-
scriptions in 1996 to 401,272 in 2005. Reimbursement per pre-
scription for all drugs, with exception of Agenerase, increased
over time. The relatively expensive drugs in 2005 included
Trizivir ($1040) and Combivir ($640), as well as Reyataz ($750),
Lexiva ($700),Sustiva ($420), Viramune ($370), and Fuzeon
($1914). CONCLUSION: The tremendous growth in antiretro-
viral spending is due in part to growing utilization of newly
developed antiretroviral drugs and in part to rising prices of
existing medications.
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OBJECTIVES: Cigarette smoking population is at high risk of
pneumococcal diseases. The study objectives are: 1) estimating
pneumococcal immunization rate in cigarette smoking popula-
tion (50 years and above), and 2) assessing the differences in
sociodemographic and health-related characteristics of those
immunized and non-immunized for pneumonia within this popu-
lation. METHODS: The study used 2005 Behavioral Risk 
Factor Surveillance System (BRFSS) survey. The smoking popu-
lation was extracted based on the question “Have you smoked
at least 100 cigarettes in your entire life?” Within this popula-
tion pneumonia vaccination status was assessed based on the
response to the question “Have you ever had a pneumonia
shot?” Descriptive, univariate, and multivariate statistics were
used to compare those immunized with those not immunized on
the basis of sociodemographic and health-related characteristics.
Data extraction and analysis were performed on weighted data
using SPSS 13.0. RESULTS: Of the total cigarette smoking popu-
lation (n = 97,342; 50 years and above), only 44.2% (n =
41,005) were immunized for pneumonia. Pneumonia immuniza-
tion rate was 31.4% in 50–64 years age group and 68.6% in 65
and above age group. Whites who smoked had a higher immu-
nization rate (71.8%) compared with non-whites (28.2%).
Those with health insurance coverage had higher immunization
rate (95.4%) than those who had no health insurance coverage
(4.6%). Immunization rates were lowest for those with educa-
tion less than high school (15.2%), followed by high school
(34.9%) and highest for greater than high school (49.9%).
Results from logistic regression indicated that those with health
care coverage (OR = 1.789) and with comorbid conditions (OR
= 1.427–2.298) were more likely to be immunized with pneu-
mococcal vaccine. CONCLUSION: Overall, the pneumococcal
immunization rate is low among cigarette smoking population.
Health care providers should identify the high-risk groups such
as those who are 50 years and above, non-whites, who lack of
health insurance coverage and should encourage them to receive
pneumococcal immunization.
